ProShare Advisors
TBPH icon

ProShare Advisors’s Theravance Biopharma TBPH Stock Holding History

ProShare Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,266
Closed -$91.7K – 2180
2025
Q1 		$91.7K Sell
10,266
-2,406
-19% -$22.4K ﹤0.01% 1851
2024
Q4 		$119K Buy
+12,672
New +$115K ﹤0.01% 2036
2024
Q2 		– Sell
-12,219
Closed -$110K – 1999
2024
Q1 		$110K Buy
12,219
+508
+4% +$4.71K ﹤0.01% 1807
2023
Q4 		$132K Buy
11,711
+933
+9% +$9.39K ﹤0.01% 1741
2023
Q3 		$93K Sell
10,778
-984
-8% -$9.5K ﹤0.01% 1646
2023
Q2 		$122K Sell
11,762
-595
-5% -$6.57K ﹤0.01% 1664
2023
Q1 		$134K Sell
12,357
-1,617
-12% -$17.1K ﹤0.01% 1532
2022
Q4 		$157K Buy
13,974
+446
+3% +$4.69K ﹤0.01% 1552
2022
Q3 		$137K Buy
13,528
+366
+3% +$3.43K ﹤0.01% 1487
2022
Q2 		$119K Sell
13,162
-5,819
-31% -$53.6K ﹤0.01% 1585
2022
Q1 		$181K Sell
18,981
-4,508
-19% -$44.2K ﹤0.01% 1907
2021
Q4 		$260K Buy
23,489
+106
+0.5% +$924 ﹤0.01% 1872
2021
Q3 		$173K Sell
23,383
-2,177
-9% -$24.4K ﹤0.01% 1820
2021
Q2 		$371K Buy
25,560
+4,193
+20% +$78.7K ﹤0.01% 1744
2021
Q1 		$436K Buy
21,367
+1,161
+6% +$22.1K ﹤0.01% 1532
2020
Q4 		$359K Buy
20,206
+4,334
+27% +$77.8K ﹤0.01% 1488
2020
Q3 		$235K Sell
15,872
-460
-3% -$8.62K ﹤0.01% 1328
2020
Q2 		$343K Buy
16,332
+5,649
+53% +$145K ﹤0.01% 1151
2020
Q1 		$247K Sell
10,683
-7,652
-42% -$192K ﹤0.01% 934
2019
Q4 		$475K Sell
18,335
-2,030
-10% -$39.5K ﹤0.01% 1087
2019
Q3 		$397K Sell
20,365
-612
-3% -$12.4K ﹤0.01% 1077
2019
Q2 		$343K Sell
20,977
-2,611
-11% -$52.9K ﹤0.01% 1173
2019
Q1 		$535K Buy
23,588
+244
+1% +$6.19K ﹤0.01% 994
2018
Q4 		$597K Sell
23,344
-4,369
-16% -$118K ﹤0.01% 886
2018
Q3 		$905K Sell
27,713
-983
-3% -$26.8K 0.01% 865
2018
Q2 		$651K Sell
28,696
-1,860
-6% -$44.2K ﹤0.01% 1002
2018
Q1 		$741K Sell
30,556
-4,791
-14% -$132K ﹤0.01% 944
2017
Q4 		$986K Buy
35,347
+2,157
+6% +$63.8K 0.01% 846
2017
Q3 		$1.14M Buy
33,190
+2,110
+7% +$69K 0.01% 700
2017
Q2 		$1.24M Sell
31,080
-1,262
-4% -$48.5K 0.01% 667
2017
Q1 		$1.19M Sell
32,342
-8,418
-21% -$269K 0.01% 692
2016
Q4 		$1.3M Buy
40,760
+6,366
+19% +$197K 0.01% 670
2016
Q3 		$1.25M Sell
34,394
-5,388
-14% -$150K 0.02% 626
2016
Q2 		$903K Buy
39,782
+8,280
+26% +$179K 0.01% 755
2016
Q1 		$592K Sell
31,502
-3,085
-9% -$50.5K 0.01% 920
2015
Q4 		$567K Buy
34,587
+6,266
+22% +$99.4K 0.01% 988
2015
Q3 		$311K Sell
28,321
-1,905
-6% -$24.3K ﹤0.01% 1131
2015
Q2 		$394K Sell
30,226
-286
-0.9% -$4.44K 0.01% 1197
2015
Q1 		$529K Buy
30,512
+4,117
+16% +$75.5K 0.01% 1143
2014
Q4 		$394K Buy
26,395
+17,049
+182% +$297K ﹤0.01% 1338
2014
Q3 		$215K Sell
9,346
-2,974
-24% -$86.3K ﹤0.01% 1937
2014
Q2 		$393K Buy
+12,320
New +$371K 0.01% 1745

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

ProShare Advisors's TBPH Position: Q2 2025 in Review

ProShare Advisors sold out of Theravance Biopharma (TBPH) in Q2 2025, closing a stake of 10,266 shares — an estimated $91.7K sold.

ProShare Advisors first reported a position in TBPH in Q2 2014 and held it in 42 quarters. The position peaked at $1.3M in Q4 2016. 135 funds tracked by Wall St. Rank hold TBPH as of Q2 2025.

  • ProShare Advisors reported no remaining Theravance Biopharma position as of Q2 2025 after selling out during the quarter.
  • ProShare Advisors sold 10,266 Theravance Biopharma shares in Q2 2025, an estimated $91.7K.
  • ProShare Advisors first reported a position in Theravance Biopharma in Q2 2014 and held it in 42 quarters.
  • ProShare Advisors's Theravance Biopharma position peaked at $1.3M in Q4 2016.
  • 135 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2025.

Based on ProShare Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.